Precision medicine in gastrointestinal pathology

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Context.-Precision medicine is the promise of individualized therapy and management of patients based on their personal biology. There are now multiple global initiatives to perform whole-genome sequencing on millions of individuals. In the United States, an early program was the Million Veteran Program, and a more recent proposal in 2015 by the president of the United States is the Precision Medicine Initiative. To implement precision medicine in routine oncology care, genetic variants present in tumors need to be matched with effective clinical therapeutics. When we focus on the current state of precision medicine for gastrointestinal malignancies, it becomes apparent that there is a mixed history of success and failure. Objective.-To present the current state of precision medicine using gastrointestinal oncology as a model. We will present currently available targeted therapeutics, promising new findings in clinical genomic oncology, remaining quality issues in genomic testing, and emerging oncology clinical trial designs. Data Sources.-Review of the literature including clinical genomic studies on gastrointestinal malignancies, clinical oncology trials on therapeutics targeted to molecular alterations, and emerging clinical oncology study designs. Conclusions.-Translating our ability to sequence thousands of genes into meaningful improvements in patient survival will be the challenge for the next decade.

Original languageEnglish (US)
Pages (from-to)449-460
Number of pages12
JournalArchives of Pathology and Laboratory Medicine
Volume140
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Precision Medicine
Medical Oncology
Pathology
State Medicine
Clinical Trials
Neoplasms
Information Storage and Retrieval
Veterans
Therapeutics
Genome
Survival
Genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Precision medicine in gastrointestinal pathology. / Wang, David H.; Park, Jason Y.

In: Archives of Pathology and Laboratory Medicine, Vol. 140, No. 5, 01.05.2016, p. 449-460.

Research output: Contribution to journalArticle

@article{88f36ff60ff44ed482025cad2841e9be,
title = "Precision medicine in gastrointestinal pathology",
abstract = "Context.-Precision medicine is the promise of individualized therapy and management of patients based on their personal biology. There are now multiple global initiatives to perform whole-genome sequencing on millions of individuals. In the United States, an early program was the Million Veteran Program, and a more recent proposal in 2015 by the president of the United States is the Precision Medicine Initiative. To implement precision medicine in routine oncology care, genetic variants present in tumors need to be matched with effective clinical therapeutics. When we focus on the current state of precision medicine for gastrointestinal malignancies, it becomes apparent that there is a mixed history of success and failure. Objective.-To present the current state of precision medicine using gastrointestinal oncology as a model. We will present currently available targeted therapeutics, promising new findings in clinical genomic oncology, remaining quality issues in genomic testing, and emerging oncology clinical trial designs. Data Sources.-Review of the literature including clinical genomic studies on gastrointestinal malignancies, clinical oncology trials on therapeutics targeted to molecular alterations, and emerging clinical oncology study designs. Conclusions.-Translating our ability to sequence thousands of genes into meaningful improvements in patient survival will be the challenge for the next decade.",
author = "Wang, {David H.} and Park, {Jason Y.}",
year = "2016",
month = "5",
day = "1",
doi = "10.5858/arpa.2015-0317-RA",
language = "English (US)",
volume = "140",
pages = "449--460",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "5",

}

TY - JOUR

T1 - Precision medicine in gastrointestinal pathology

AU - Wang, David H.

AU - Park, Jason Y.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Context.-Precision medicine is the promise of individualized therapy and management of patients based on their personal biology. There are now multiple global initiatives to perform whole-genome sequencing on millions of individuals. In the United States, an early program was the Million Veteran Program, and a more recent proposal in 2015 by the president of the United States is the Precision Medicine Initiative. To implement precision medicine in routine oncology care, genetic variants present in tumors need to be matched with effective clinical therapeutics. When we focus on the current state of precision medicine for gastrointestinal malignancies, it becomes apparent that there is a mixed history of success and failure. Objective.-To present the current state of precision medicine using gastrointestinal oncology as a model. We will present currently available targeted therapeutics, promising new findings in clinical genomic oncology, remaining quality issues in genomic testing, and emerging oncology clinical trial designs. Data Sources.-Review of the literature including clinical genomic studies on gastrointestinal malignancies, clinical oncology trials on therapeutics targeted to molecular alterations, and emerging clinical oncology study designs. Conclusions.-Translating our ability to sequence thousands of genes into meaningful improvements in patient survival will be the challenge for the next decade.

AB - Context.-Precision medicine is the promise of individualized therapy and management of patients based on their personal biology. There are now multiple global initiatives to perform whole-genome sequencing on millions of individuals. In the United States, an early program was the Million Veteran Program, and a more recent proposal in 2015 by the president of the United States is the Precision Medicine Initiative. To implement precision medicine in routine oncology care, genetic variants present in tumors need to be matched with effective clinical therapeutics. When we focus on the current state of precision medicine for gastrointestinal malignancies, it becomes apparent that there is a mixed history of success and failure. Objective.-To present the current state of precision medicine using gastrointestinal oncology as a model. We will present currently available targeted therapeutics, promising new findings in clinical genomic oncology, remaining quality issues in genomic testing, and emerging oncology clinical trial designs. Data Sources.-Review of the literature including clinical genomic studies on gastrointestinal malignancies, clinical oncology trials on therapeutics targeted to molecular alterations, and emerging clinical oncology study designs. Conclusions.-Translating our ability to sequence thousands of genes into meaningful improvements in patient survival will be the challenge for the next decade.

UR - http://www.scopus.com/inward/record.url?scp=84965056848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965056848&partnerID=8YFLogxK

U2 - 10.5858/arpa.2015-0317-RA

DO - 10.5858/arpa.2015-0317-RA

M3 - Article

VL - 140

SP - 449

EP - 460

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 5

ER -